...
首页> 外文期刊>American journal of respiratory and critical care medicine >Antibody to Surfactant Protein A Increases Sensitivity of Pulmonary Surfactant to Inactivation by Fibrinogen in vivo
【24h】

Antibody to Surfactant Protein A Increases Sensitivity of Pulmonary Surfactant to Inactivation by Fibrinogen in vivo

机译:表面活性剂蛋白A的抗体增加了肺表面活性剂对体内纤维蛋白原失活的敏感性。

获取原文
获取原文并翻译 | 示例

摘要

It has been suggested that surfactant protein-A (SP-A) protects surfactant activity from inhibitors such as fibrinogen. Substantial evidence indicates that, inhibition of surfactant activity is often important in the pathogenesis of acute respiratory failure. Studies on surfactant function in the pulsating bubble surfactometer imply that SP-A helps to maintain low surface tension in the presence of inhibitors such as fibrinogen. We tested whether SP-A acts in this way in vivo. Rabbit pups, 29 d gestational age, were treated with a monoclonal antibody to rabbit SP-A (R5) followed by fibrinogen, or with control preparations (normal IgC and saline, respectively). Lung compliance was measured during ventilation throughout these experiments. Air-space volume and pulmonary edema were quantitated morphometrically. Animals receiving anti-SP-A antibody + fibrinogen showed substantial and significant impairment in lung compliance compared with control littermates receiving normal IgC and/or saline. Lungs from these animals showed decreased pulmonary air-space volume and increased alveolar edema. We conclude that SP-A protects pulmonary surfactant from inhibition by fibrinogen in vivo. This protective activity may be important in the pathogenesis of both adult and neonatal respiratory distress syndromes, and it may also be useful in devising therapies for these diseases.
机译:已经提出表面活性剂蛋白A(SP-A)保护表面活性剂免受诸如纤维蛋白原的抑制剂的作用。大量证据表明,在急性呼吸衰竭的发病机理中,抑制表面活性剂的活性通常很重要。对脉动气泡表面计中表面活性剂功能的研究表明,SP-A在存在抑制剂(如纤维蛋白原)的情况下有助于保持较低的表面张力。我们测试了SP-A是否在体内以这种方式起作用。用抗兔SP-A的单克隆抗体(R5),纤维蛋白原或对照制剂(分别为正常的IgC和生理盐水)处理胎龄为29 d的家兔。在整个实验过程中,在通气期间测量肺顺应性。空洞体积和肺水肿的形态计量。与接受正常IgC和/或生理盐水的对照同窝仔猪相比,接受抗SP-A抗体+纤维蛋白原的动物肺部顺应性明显受损。这些动物的肺显示出肺气腔容积减少和肺泡水肿增加。我们得出结论,SP-A保护肺表面活性剂免受体内纤维蛋白原的抑制。这种保护活性在成人和新生儿呼吸窘迫综合征的发病机理中可能都是重要的,并且在设计针对这些疾病的疗法中也可能有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号